| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
Form 4: Meek David D., Director
Sold 9,080 shares ($193K) |
| 06 Nov 2026 | 144 |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~ |
| 03 Nov 2026 |
Form 4: Abi-Saab Walid, Chief Medical Officer
Received 18,750 shares as a grant or award |
| 02 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease |
| 16 Oct 2026 | SCHEDULE 13G/A |
| 29 Sep 2026 |
8-K: Regulation FD Disclosure
Ashley – Huntington’s Disease Community Advocate Phase I/II ifezuntirgene inilparvovec (AMT-130) Huntington’s Disease Program Update September 29, 2026 |
| 02 Sep 2026 |
8-K: Regulation FD Disclosure
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 29 Jul 2026 | S-8 |
| 29 Jul 2026 | 10-Q |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition
~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ |
| 20 Jul 2026 | SCHEDULE 13G/A |
| 16 Jul 2026 | SCHEDULE 13G |
| 07 Jul 2026 |
Form 4: Kapusta Matthew C, Director
Received 21,082 shares by exercise or conversion ($409K) · Sold 21,082 shares ($952K) |
| 02 Jul 2026 |
Form 4: Abi-Saab Walid, Chief Medical Officer
Received 10,000 shares by exercise or conversion ($55.9K) · Sold 30,000 shares ($1.39M) |
| 02 Jul 2026 |
Form 4: Kaye Jack, Director
Received 21,167 shares by exercise or conversion ($496K) · Sold 21,167 shares ($983K) |
| 02 Jul 2026 | 144 |
Loading...